College of Medicine
Liao Lab
Led by Daiqing Liao · Physiology and Aging
What we study
The Liao Lab studies cancer signaling, metabolism, and epigenetics, focusing on small molecule inhibitors and degraders of histone deacetylases and acetyltransferases. They use breast cancer models and mouse tumor models to explore epigenetic pathways and develop potential cancer therapies.
What working here is like
- Wet lab
- Computational
- Mice
- Cells in a dish
- Coding required
- Projects
- 4
- Papers
- 5
Current projects
Enhancing Immunotherapy Treatment Response with a Novel Molecular Glue Degrader of the CoREST Complex in Triple-Negative Breast Cancer
Developing a degrader to improve immunotherapy for triple-negative breast cancer.
Lipid metabolism in triple-negative breast cancer biology and therapy
Exploring lipid metabolism in triple-negative breast cancer to identify therapeutic targets.
Show 2 more projectsShow fewer
Analyzing the Effects of HDACi and PROTACs on Gene Expression
The project uses machine learning to predict how cancer drugs called HDAC inhibitors and PROTACs change gene activity in different cancer cell lines. Students will train models on data from the Cancer Cell Line Encyclopedia and test predictions for new drug treatments.
From the Spring 2025 UF Undergraduate Research Symposium · abstract book, p. 399
Exploring the Role of DAXX and mTOR in Oncogenic Lipogenesis
The lab studies how two proteins, DAXX and mTOR, help cancer cells make more fats for growth. Students use microscopy to see where these proteins are inside cells and how they might work together.
From the Spring 2025 UF Undergraduate Research Symposium · abstract book, p. 122
Summaries are written by AI in plain language from public symposium abstracts and may be imperfect.
Recent papers, explained
- A 2-in-1 Strategy for the Discovery of Compact HDAC8 Protac Degraders
2026 · Journal of Medicinal Chemistry
Designs smaller, more effective drugs to break down a protein.
- Proteolysis Targeting Chimera Loaded Extracellular Vesicles for Developing Triple Negative Breast Cancer Treatment
2025 · Journal of Extracellular Vesicles
Uses tiny bubbles to deliver cancer drugs more effectively.
Show 3 more papersShow fewer
- Discovery of a Highly Potent and Selective HDAC8 Degrader: Advancing the Functional Understanding and Therapeutic Potential of HDAC8
2024 · Journal of Medicinal Chemistry
Creates a new drug to target a protein linked to cancer.
- Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy
2023 · Life Medicine
Tests whether targeting proteins inside cancer cells can improve immunotherapy for non-immunogenic tumors.
- HDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation
2023 · Cell chemical biology
Plain-language summaries are AI-written and reviewed by us; check the paper for details.
How to reach out
Daiqing Liao hasn't set up this page yet. You can also look them up in the UF directory (search “Daiqing Liao”).